CCM® Around the World: What's Next for CCM® Therapy and How Might it Influence Your Work?

September 2, 2020

In this video, Dr. Daniel Burkhoff discusses CCM® Therapy and the clinical data and the strategy of implementing it into Heart Failure Treatment.

  • October 26, 2021 - U.S. Food and Drug Administration approved a modification of labeling for the Optimizer® Smart medical device, allowing the removal of “normal sinus rhythm” (NSR) from the indications for use statement as of 10/26/2021. Please note that this presentation was done prior to this FDA update.
Login to view comments. Click here to Login